Application of dihydroartemisinin and quinolone conjugate in preparation of drugs for resisting leishmania
A quinolone conjugate, dihydroartemisinin technology, applied in the direction of anti-infective drugs, drug combinations, resistance to vector-borne diseases, etc., can solve the safety and toxicity problems of leishmaniasis, lack of compliance, and drug resistance and other issues to achieve the effect of broadening the use of pharmaceuticals
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0035] Embodiment 1. Preparation of target compound
[0036] 1. Synthesis of the target compound TM1 series
[0037] The target compounds TM1 series (TM1-1~TM1-12) were prepared according to the method described in Chinese patent 104418864B (conjugates of dihydroartemisinin and quinolones and their preparation methods and applications).
[0038]
[0039]
[0040] 2. Synthesis of the target compound TM9 series
[0041] 1) Synthesis of intermediate IM3
[0042] The intermediate IM3 was prepared according to the method described in Chinese patent 104418864B (conjugates of dihydroartemisinin and quinolones and its preparation method and application).
[0043] 2) Synthesis of target compound TM9 series
[0044]
[0045] Add IM3 (1mmol) and 3mL of dichloromethane (DCM) into a 100mL reaction flask, stir at -10°C to 0°C, and partially dissolve, then add N,N'-diisopropylethylamine (DIPEA, 1.5mmol) in sequence , Pivaloyl chloride (1.5mmol), -10 ℃ ~ 0 ℃ continue to stir the ...
Embodiment 2
[0078] Example 2. Anti-Leishmania activity test of target compound
[0079] The anti-Leishmania activity of the target compound was tested by the Open Innovation Drug Discovery (OIDD) program of Eli Lilly and Company in the United States. First, a single-concentration primary screening (Primary SP) was carried out, and then a multi-concentration test (Primary CRC ). The test results of anti-Leishmania activity of some compounds are shown in Table 3.
[0080] Anti-Leishmania activity test results of some compounds in table 3
[0081]
[0082] The Primary SP test results in Table 3 show that the target compounds TM1, TM9, TM10, and TM11-1 can all inhibit the growth of Leishmania donovani (L.donovani), wherein TM9-1, TM9-2, TM9-3, and TM9 -5 The growth inhibition rate of Leishmania donovani at 5 μM test concentration is close to or exceeds 95%; Primary CRC test results show that the pIC of the target compounds TM1, TM9 and TM10 on the growth of Leishmania donovani 50 (Negat...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com